company background image
ATH

Alterity TherapeuticsASX:ATH Stock Report

Market Cap

AU$72.2m

7D

-6.3%

1Y

-23.1%

Updated

20 Oct, 2021

Data

Company Financials +
ATH fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ATH Overview

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia.

Price History & Performance

Summary of all time highs, changes and price drops for Alterity Therapeutics
Historical stock prices
Current Share PriceAU$0.03
52 Week HighAU$0.024
52 Week LowAU$0.053
Beta1.12
1 Month Change0%
3 Month Change-9.09%
1 Year Change-23.08%
3 Year Change-31.82%
5 Year Change-55.88%
Change since IPO-97.06%

Recent News & Updates

Shareholder Returns

ATHAU BiotechsAU Market
7D-6.3%1.1%1.7%
1Y-23.1%1.7%20.2%

Return vs Industry: ATH underperformed the Australian Biotechs industry which returned 1.7% over the past year.

Return vs Market: ATH underperformed the Australian Market which returned 20.2% over the past year.

Price Volatility

Is ATH's price volatile compared to industry and market?
ATH volatility
ATH Beta1.12
Industry Beta1.62
Market Beta1

Stable Share Price: ATH is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: ATH's weekly volatility has decreased from 13% to 8% over the past year.

About the Company

FoundedEmployeesCEOWebsite
199711David Stamlerhttps://alteritytherapeutics.com

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson’s disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer’s disease.

Alterity Therapeutics Fundamentals Summary

How do Alterity Therapeutics's earnings and revenue compare to its market cap?
ATH fundamental statistics
Market CapAU$72.21m
Earnings (TTM)-AU$15.31m
Revenue (TTM)AU$4.34m

16.7x

P/S Ratio

-4.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ATH income statement (TTM)
RevenueAU$4.34m
Cost of RevenueAU$360.03k
Gross ProfitAU$3.98m
ExpensesAU$19.29m
Earnings-AU$15.31m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.0064
Gross Margin91.70%
Net Profit Margin-352.78%
Debt/Equity Ratio0%

How did ATH perform over the long term?

See historical performance and comparison

Valuation

Is Alterity Therapeutics undervalued compared to its fair value and its price relative to the market?

2.37x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ATH's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ATH's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ATH is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.

PE vs Market: ATH is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ATH's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ATH is good value based on its PB Ratio (2.4x) compared to the AU Biotechs industry average (4.8x).


Future Growth

How is Alterity Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

11.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if ATH's forecast earnings growth is above the savings rate (1.9%).

Earnings vs Market: Insufficient data to determine if ATH's earnings are forecast to grow faster than the Australian market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if ATH's revenue is forecast to grow faster than the Australian market.

High Growth Revenue: Insufficient data to determine if ATH's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ATH's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Alterity Therapeutics performed over the past 5 years?

-17.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ATH is currently unprofitable.

Growing Profit Margin: ATH is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ATH is unprofitable, and losses have increased over the past 5 years at a rate of 17.4% per year.

Accelerating Growth: Unable to compare ATH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ATH is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (46.5%).


Return on Equity

High ROE: ATH has a negative Return on Equity (-50.24%), as it is currently unprofitable.


Financial Health

How is Alterity Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: ATH's short term assets (A$33.5M) exceed its short term liabilities (A$3.1M).

Long Term Liabilities: ATH's short term assets (A$33.5M) exceed its long term liabilities (A$47.7K).


Debt to Equity History and Analysis

Debt Level: ATH is debt free.

Reducing Debt: ATH has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ATH has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ATH has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 13.9% each year.


Dividend

What is Alterity Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ATH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ATH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ATH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ATH's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ATH's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

8.3yrs

Average management tenure


CEO

David Stamler (60 yo)

0.75

Tenure

AU$978,901

Compensation

Dr. David A. Stamler, M.D., serves as Chief Executive Officer at Alterity Therapeutics Limited since January 07, 2021. Dr. Stamler had been the Chief Medical Officer and Senior Vice President of Clinical D...


CEO Compensation Analysis

Compensation vs Market: David's total compensation ($USD731.89K) is above average for companies of similar size in the Australian market ($USD302.06K).

Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: ATH's management team is seasoned and experienced (8.3 years average tenure).


Board Members

Experienced Board: ATH's board of directors are seasoned and experienced ( 14.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 121.8%.


Top Shareholders

Company Information

Alterity Therapeutics Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Alterity Therapeutics Limited
  • Ticker: ATH
  • Exchange: ASX
  • Founded: 1997
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$72.206m
  • Shares outstanding: 2.41b
  • Website: https://alteritytherapeutics.com

Number of Employees


Location

  • Alterity Therapeutics Limited
  • 460 Bourke Street
  • Level 3
  • Melbourne
  • Victoria
  • 3000
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/20 15:17
End of Day Share Price2021/10/20 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.